

## CORRECTED VERSION

(19) World Intellectual Property  
Organization  
International Bureau



(10) International Publication Number

WO 2018/127919 A9

(43) International Publication Date  
12 July 2018 (12.07.2018)

WIPO | PCT

## (51) International Patent Classification:

C07K 14/705 (2006.01) C07K 19/00 (2006.01)  
A61K 38/17 (2006.01) A61P 35/00 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

## (21) International Application Number:

PCT/IL2018/050017

## Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

## (22) International Filing Date:

04 January 2018 (04.01.2018)

## Published:

— with international search report (Art. 21(3))  
— with sequence listing part of description (Rule 5.2(a))

## (25) Filing Language:

English

## (26) Publication Language:

English

## (48) Date of publication of this corrected version:

13 December 2018 (13.12.2018)

## (30) Priority Data:

62/442,469 05 January 2017 (05.01.2017) US

## (15) Information about Correction:

see Notice of 13 December 2018 (13.12.2018)

(71) Applicant: **KAHR MEDICAL LTD.** [IL/IL]; 1 Kiryat  
Hadassa, JDP Building, 4th Floor, 9112001 Jerusalem (IL).

(72) Inventors: **SHANI, Noam**; 12 Sapir Street, 30900  
Zikhron-Yaakov (IL). **GOZLAN, Yosi**; 42a Harei Edom  
Street, 7661308 Rehovot (IL). **DRANITZKI ELHALEL,**  
**Michal**; 138 HaSheizaf Street, 9086000 Shoresht (IL).  
**BREMER, Edwin**; Mozartstraat 26, 9722ED Groningen  
(NL). **KAMINSKY, Ido**; 11 Shkediya Street, 5244711 Ra-  
mat-Gan (IL).

(74) Agent: **EHRlich, Gal** et al.; G. E. EHRlich (1995)  
LTD., 11 Menachem Begin Road, 5268104 Ramat Gan (IL).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,  
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,  
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,  
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,  
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: A SIRPalpha-41BBL FUSION PROTEIN AND METHODS OF USE THEREOF

(57) Abstract: SIRPalpha-41BBL fusion proteins are provided. Accordingly, there is provided a SIRPalpha-41BBL fusion protein comprising a single amino acid linker between the SIRPalpha and the 41BBL. Also there is provided a SIRPalpha-41BBL fusion protein in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the SIRPalpha-41BBL fusion protein, host-cells expressing the SIRPalpha-41BBL fusion protein and methods of use thereof.

WO 2018/127919 A9